Eli Lilly and Company $LLY is First American Bank’s 7th Largest Position

First American Bank reduced its position in shares of Eli Lilly and Company (NYSE:LLY) by 2.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 51,068 shares of the company’s stock after selling 1,088 shares during the period. Eli Lilly and Company accounts for about 3.3% of First American Bank’s portfolio, making the stock its 7th largest holding. First American Bank’s holdings in Eli Lilly and Company were worth $54,882,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of LLY. Brighton Jones LLC increased its stake in Eli Lilly and Company by 22.0% during the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after buying an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC grew its position in shares of Eli Lilly and Company by 2.8% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after purchasing an additional 40 shares in the last quarter. Schnieders Capital Management LLC. grew its position in shares of Eli Lilly and Company by 16.7% in the second quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company’s stock valued at $6,231,000 after purchasing an additional 1,141 shares in the last quarter. Flow Traders U.S. LLC purchased a new stake in shares of Eli Lilly and Company in the second quarter valued at approximately $356,000. Finally, Jump Financial LLC purchased a new stake in shares of Eli Lilly and Company in the second quarter valued at approximately $6,680,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. TD Cowen upped their price target on Eli Lilly and Company from $960.00 to $1,250.00 and gave the company a “buy” rating in a research report on Thursday, January 29th. Bank of America upped their price target on Eli Lilly and Company from $1,293.00 to $1,294.00 and gave the company a “buy” rating in a research report on Thursday, April 2nd. Royal Bank Of Canada assumed coverage on Eli Lilly and Company in a research report on Tuesday, February 24th. They issued an “outperform” rating and a $1,250.00 price target for the company. Truist Financial restated a “buy” rating on shares of Eli Lilly and Company in a research report on Monday, February 23rd. Finally, The Goldman Sachs Group set a $1,260.00 price target on Eli Lilly and Company in a research report on Thursday, February 5th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $1,222.22.

Eli Lilly and Company Trading Up 0.3%

Shares of Eli Lilly and Company stock opened at $930.08 on Wednesday. The firm has a market capitalization of $878.76 billion, a price-to-earnings ratio of 40.53, a PEG ratio of 1.09 and a beta of 0.51. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,133.95. The company has a debt-to-equity ratio of 1.54, a quick ratio of 1.19 and a current ratio of 1.58. The stock has a 50 day moving average of $988.75 and a 200 day moving average of $973.25.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, topping the consensus estimate of $7.48 by $0.06. The company had revenue of $19.29 billion during the quarter, compared to analyst estimates of $17.85 billion. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The firm’s revenue for the quarter was up 42.6% compared to the same quarter last year. During the same period in the prior year, the business posted $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA approval of Foundayo creates a new high‑value product opportunity that could add billions to sales and validate Lilly’s oral GLP‑1 strategy. Great News for Eli Lilly Stock Investors!
• Positive Sentiment: CEO Dave Ricks says Lilly is ready to scale production of Foundayo, reducing execution risk and supporting faster commercialization. Eli Lilly CEO Says Company Ready to Scale Production
• Positive Sentiment: Lilly will manufacture the GLP‑1 at a new Houston facility, supporting supply and limiting bottlenecks as demand ramps. Lilly’s $6.5B Houston plant will make its new FDA-approved GLP-1
• Positive Sentiment: Brokerage reaction includes modest price‑target increases and renewed analyst attention, reflecting confidence in Foundayo’s sales potential despite valuation questions. Price Target Raised Following FDA Approval
• Neutral Sentiment: Lilly amended its collaboration with AC Immune to advance next‑generation Tau aggregation inhibitors with IND‑enabling studies planned in 2026 — diversification into neurodegeneration could be material longer term but won’t move near‑term revenue. Eli Lilly Extends AC Immune Tau Pact
• Negative Sentiment: Pricing pressure: Novo Nordisk launched a lower‑priced Wegovy HD at about a 40% lower cash price than Lilly’s offering, raising concerns that price competition could blunt Foundayo’s revenue and margins. Novo Nordisk Unveils $399 Wegovy HD
• Negative Sentiment: Market commentary flags a broader GLP‑1 price war and side‑effect/competition concerns that have driven short‑term profit‑taking and tempered the stock’s post‑approval rally. Price War Dampens Lilly Surge After Oral GLP-1 Wins FDA Nod

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.